• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

OCT1 和 OCT2 对多特异性药物和外源性化学物质识别的分子基础。

Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2.

机构信息

Department of Biochemistry, Duke University School of Medicine, Durham, NC, USA.

Departments of Biological Sciences, Chemistry, and Bioengineering, Lehigh University, Bethlehem, PA, USA.

出版信息

Nat Struct Mol Biol. 2023 Jul;30(7):1001-1011. doi: 10.1038/s41594-023-01017-4. Epub 2023 Jun 8.

DOI:10.1038/s41594-023-01017-4
PMID:37291422
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10895701/
Abstract

A wide range of endogenous and xenobiotic organic ions require facilitated transport systems to cross the plasma membrane for their disposition. In mammals, organic cation transporter (OCT) subtypes 1 and 2 (OCT1 and OCT2, also known as SLC22A1 and SLC22A2, respectively) are polyspecific transporters responsible for the uptake and clearance of structurally diverse cationic compounds in the liver and kidneys, respectively. Notably, it is well established that human OCT1 and OCT2 play central roles in the pharmacokinetics and drug-drug interactions of many prescription medications, including metformin. Despite their importance, the basis of polyspecific cationic drug recognition and the alternating access mechanism for OCTs have remained a mystery. Here we present four cryo-electron microscopy structures of apo, substrate-bound and drug-bound OCT1 and OCT2 consensus variants, in outward-facing and outward-occluded states. Together with functional experiments, in silico docking and molecular dynamics simulations, these structures uncover general principles of organic cation recognition by OCTs and provide insights into extracellular gate occlusion. Our findings set the stage for a comprehensive structure-based understanding of OCT-mediated drug-drug interactions, which will prove critical in the preclinical evaluation of emerging therapeutics.

摘要

许多内源性和外源性有机离子需要通过易化转运系统穿过质膜进行处置。在哺乳动物中,有机阳离子转运体(OCT)亚型 1 和 2(OCT1 和 OCT2,分别也称为 SLC22A1 和 SLC22A2)是多特异性转运体,分别负责肝脏和肾脏中结构多样的阳离子化合物的摄取和清除。值得注意的是,已经充分证实,人源 OCT1 和 OCT2 在许多处方药(包括二甲双胍)的药代动力学和药物相互作用中起着核心作用。尽管它们很重要,但多特异性阳离子药物识别的基础和 OCT 的交替访问机制仍然是一个谜。在这里,我们展示了apo、底物结合和药物结合的 OCT1 和 OCT2 共识变体的四个冷冻电镜结构,处于向外开放和向外闭塞状态。结合功能实验、计算对接和分子动力学模拟,这些结构揭示了 OCT 识别有机阳离子的一般原则,并提供了对外界门控阻塞的深入了解。我们的发现为基于结构的 OCT 介导的药物相互作用的全面理解奠定了基础,这对于新兴治疗药物的临床前评估将是至关重要的。

相似文献

1
Molecular basis of polyspecific drug and xenobiotic recognition by OCT1 and OCT2.OCT1 和 OCT2 对多特异性药物和外源性化学物质识别的分子基础。
Nat Struct Mol Biol. 2023 Jul;30(7):1001-1011. doi: 10.1038/s41594-023-01017-4. Epub 2023 Jun 8.
2
Molecular basis of polyspecific drug binding and transport by OCT1 and OCT2.有机阳离子转运体1和2介导多特异性药物结合与转运的分子基础
bioRxiv. 2023 Mar 16:2023.03.15.532610. doi: 10.1101/2023.03.15.532610.
3
Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations.小鼠体内有机阳离子转运体1和2(Oct1/Oct2 [Slc22a1/Slc22a2])的缺陷消除了有机阳离子的肾脏分泌。
Mol Cell Biol. 2003 Nov;23(21):7902-8. doi: 10.1128/MCB.23.21.7902-7908.2003.
4
Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant.鉴定人有机阳离子转运蛋白 1(OCT1/SLC22A1)和 OCT2(SLC22A2)介导的 1-(2-甲氧基乙基)-2-甲基-4,9-二氧代-3-(哒嗪-2-基甲基)-4,9-二氢-1H-萘并[2,3-d]咪唑鎓溴化物(YM155 单溴化物)的转运,YM155 单溴化物是一种新型小分子存活素抑制剂。
Drug Metab Dispos. 2010 Jan;38(1):1-4. doi: 10.1124/dmd.109.028142.
5
Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).伊立替康通过抑制有机阳离子转运蛋白 1(OCT1)和 2(OCT2)改变吗啡的处置。
Pharm Res. 2018 Oct 25;35(12):243. doi: 10.1007/s11095-018-2526-y.
6
Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3.多胺通过多特异性有机阳离子转运体 OCT1、OCT2 和 OCT3 的转运。
Mol Pharm. 2013 Apr 1;10(4):1450-8. doi: 10.1021/mp400024d. Epub 2013 Mar 19.
7
Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1).表达人类有机阳离子转运体1(OCT1,SLC22A1)和外排泵MDR1 P-糖蛋白(ABCB1)的双转染细胞对植物生物碱小檗碱的向量运输。
Naunyn Schmiedebergs Arch Pharmacol. 2008 Feb;376(6):449-61. doi: 10.1007/s00210-007-0219-x. Epub 2007 Dec 19.
8
Structural basis of promiscuous substrate transport by Organic Cation Transporter 1.有机阳离子转运体1介导的多底物转运的结构基础
Nat Commun. 2023 Oct 11;14(1):6374. doi: 10.1038/s41467-023-42086-9.
9
Interplay of the Organic Cation Transporters OCT1 and OCT2 with the Apically Localized Export Protein MATE1 for the Polarized Transport of Trospium.有机阳离子转运体 OCT1 和 OCT2 与顶端定位的外排蛋白 MATE1 相互作用,共同促进托品的极性转运。
Mol Pharm. 2019 Feb 4;16(2):510-517. doi: 10.1021/acs.molpharmaceut.8b00779. Epub 2019 Jan 18.
10
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs).质子泵抑制剂抑制有机阳离子转运体(OCTs)摄取二甲双胍。
PLoS One. 2011;6(7):e22163. doi: 10.1371/journal.pone.0022163. Epub 2011 Jul 14.

引用本文的文献

1
Metformin and Adipose Tissue: A Multifaceted Regulator in Metabolism, Inflammation, and Regeneration.二甲双胍与脂肪组织:代谢、炎症及再生过程中的多面调节因子
Endocrinol Metab (Seoul). 2025 Aug;40(4):523-538. doi: 10.3803/EnM.2025.2371. Epub 2025 Aug 8.
2
Substrate Specificity of the Organic Cation Transporters MATE1 and MATE2K and Functional Overlap with OCT1 and OCT2.有机阳离子转运体MATE1和MATE2K的底物特异性以及与OCT1和OCT2的功能重叠
J Med Chem. 2025 Jun 26;68(12):12473-12492. doi: 10.1021/acs.jmedchem.5c00056. Epub 2025 Jun 13.
3
Molecular basis of the urate transporter URAT1 inhibition by gout drugs.痛风药物对尿酸转运体URAT1的抑制作用的分子基础。
Nat Commun. 2025 Jun 4;16(1):5178. doi: 10.1038/s41467-025-60480-3.
4
Substrate-specific inhibition of organic cation transporter 1 revealed using a multisubstrate drug cocktail.使用多底物药物混合物揭示有机阳离子转运体1的底物特异性抑制作用。
Drug Metab Dispos. 2025 May;53(5):100074. doi: 10.1016/j.dmd.2025.100074. Epub 2025 Mar 28.
5
Energetic and structural control of polyspecificity in a multidrug transporter.多药转运蛋白中多特异性的能量和结构控制
bioRxiv. 2025 Apr 10:2025.04.09.647630. doi: 10.1101/2025.04.09.647630.
6
Verapamil and its metabolite norverapamil inhibit the MmpS5L5 efflux pump to increase bedaquiline activity.维拉帕米及其代谢产物去甲维拉帕米可抑制MmpS5L5外排泵,从而增强贝达喹啉的活性。
Proc Natl Acad Sci U S A. 2025 Apr 22;122(16):e2426827122. doi: 10.1073/pnas.2426827122. Epub 2025 Apr 17.
7
Structural Basis for Inhibition of Urate Reabsorption in URAT1.URAT1中尿酸重吸收抑制的结构基础
JACS Au. 2025 Feb 23;5(3):1308-1319. doi: 10.1021/jacsau.4c01188. eCollection 2025 Mar 24.
8
Substrate-specific effects point to the important role of Y361 as part of the YER motif in closing the binding pocket of OCT1.底物特异性效应表明,Y361作为YER基序的一部分,在封闭OCT1的结合口袋中起着重要作用。
J Biol Chem. 2025 Apr;301(4):108318. doi: 10.1016/j.jbc.2025.108318. Epub 2025 Feb 14.
9
Structures and membrane interactions of human OAT1 in complex with clinical used drugs.人OAT1与临床使用药物复合物的结构及膜相互作用
Sci Adv. 2025 Feb 14;11(7):eads5405. doi: 10.1126/sciadv.ads5405.
10
Cryo-EM structure of the botulinum neurotoxin A/SV2B complex and its implications for translocation.肉毒杆菌神经毒素A/SV2B复合物的冷冻电镜结构及其对转位的影响。
Nat Commun. 2025 Feb 11;16(1):1224. doi: 10.1038/s41467-025-56304-z.

本文引用的文献

1
Structural basis of organic cation transporter-3 inhibition.有机阳离子转运蛋白 3 抑制的结构基础。
Nat Commun. 2022 Nov 7;13(1):6714. doi: 10.1038/s41467-022-34284-8.
2
Methotrexate recognition by the human reduced folate carrier SLC19A1.人源二氢叶酸还原酶载体 SLC19A1 对甲氨蝶呤的识别。
Nature. 2022 Sep;609(7929):1056-1062. doi: 10.1038/s41586-022-05168-0. Epub 2022 Sep 7.
3
Structural basis for proton coupled cystine transport by cystinosin.胱氨酸转运蛋白介导的质子偶联胱氨酸转运的结构基础。
Nat Commun. 2022 Aug 17;13(1):4845. doi: 10.1038/s41467-022-32589-2.
4
Recent advances on the inhibition of human solute carriers: Therapeutic implications and mechanistic insights.近年来人类溶质载体抑制剂的研究进展:治疗意义和机制见解。
Curr Opin Struct Biol. 2022 Jun;74:102378. doi: 10.1016/j.sbi.2022.102378. Epub 2022 Apr 26.
5
Amino acids in transmembrane helix 1 confer major functional differences between human and mouse orthologs of the polyspecific membrane transporter OCT1.跨膜螺旋 1 中的氨基酸赋予多特异性膜转运蛋白 OCT1 的人源和鼠源同源物之间的主要功能差异。
J Biol Chem. 2022 Jun;298(6):101974. doi: 10.1016/j.jbc.2022.101974. Epub 2022 Apr 22.
6
High-speed high-resolution data collection on a 200 keV cryo-TEM.在200 keV低温透射电子显微镜上进行高速高分辨率数据采集。
IUCrJ. 2022 Jan 29;9(Pt 2):243-252. doi: 10.1107/S2052252522000069. eCollection 2022 Mar 1.
7
Molecular basis for stereoselective transport of fenoterol by the organic cation transporters 1 and 2.有机阳离子转运体 1 和 2 对芬特罗立体选择性转运的分子基础。
Biochem Pharmacol. 2022 Mar;197:114871. doi: 10.1016/j.bcp.2021.114871. Epub 2021 Dec 10.
8
Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advanced testing.药物-药物相互作用在有机阳离子转运体方面的最新进展:机制、临床影响及先进检测方法的建议。
Expert Opin Drug Metab Toxicol. 2021 Jun;17(6):635-653. doi: 10.1080/17425255.2021.1915284. Epub 2021 Jun 9.
9
Structures and General Transport Mechanisms by the Major Facilitator Superfamily (MFS).主要易化超家族(MFS)的结构和一般转运机制。
Chem Rev. 2021 May 12;121(9):5289-5335. doi: 10.1021/acs.chemrev.0c00983. Epub 2021 Apr 22.
10
Identification of Novel High-Affinity Substrates of OCT1 Using Machine Learning-Guided Virtual Screening and Experimental Validation.利用机器学习引导的虚拟筛选和实验验证鉴定新型OCT1高亲和力底物
J Med Chem. 2021 Mar 11;64(5):2762-2776. doi: 10.1021/acs.jmedchem.0c02047. Epub 2021 Feb 19.